^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses

Excerpt:
Heterogeneous patterns of drug response to RAF and MEK inhibitors of cell lines harboring BRAF fusions compared toBRAFV600E mutant lines...Cell lines with BRAF fusions, except SK-MEL-23, demonstrated resistance to PLX8394, a BRAF inhibitor developed as a “paradox breaker...
DOI:
10.1016/j.celrep.2019.09.009